Article Text

Download PDFPDF
Pharmacokinetic/pharmacodynamic analysis of vancomycin in patients with Enterococcus faecium bacteraemia: a retrospective cohort study
  1. Naohiro Tochikura1,
  2. Chiaki Matsumoto1,
  3. So Iwabuchi1,
  4. Hiroya Aso1,
  5. Sakae Fukushima1,
  6. Susumu Ootsuka1,
  7. Nobuhiro Ooba2,
  8. Masaki Ishihara3,
  9. Hideto Nakajima3,
  10. Hiroshi Umemura4,
  11. Tomohiro Nakayama4
  1. 1 Department of Pharmacy, Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan
  2. 2 Department of Clinical Pharmacy, Nihon University School of Pharmacy, Funabashi, Chiba, Japan
  3. 3 Division of Neurology, Department of Medicine, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan
  4. 4 Division of Laboratory Medicine, Department of Pathology and Microbiology, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan
  1. Correspondence to Dr Nobuhiro Ooba; ooba.nobuhiro{at}nihon-u.ac.jp

Abstract

Objectives The trough concentration of vancomycin and the area under the concentration–time curve (AUC)/minimum inhibitory concentration (MIC) ratio are crucial in determining vancomycin efficacy against methicillin-resistant Staphylococcus aureus. However, the use of similar pharmacokinetic principles in determining antibiotic efficacy against other gram-positive cocci is lacking. We performed a pharmacokinetic/pharmacodynamic analysis (association of target trough concentration values and AUC/MIC with therapeutic outcome) of vancomycin in patients with Enterococcus faecium bacteraemia.

Methods Between January 2014 and December 2021 we performed a retrospective cohort study of patients with E. faecium bacteraemia treated with vancomycin. Patients who received renal replacement therapy or had chronic kidney disease were excluded. Clinical failure, the primary outcome, was defined as a composite of 30-day all-cause mortality, vancomycin-susceptible infection requiring change of treatment, and/or recurrence. AUC24 was estimated using a Bayesian estimation approach based on an individual vancomycin trough concentration. The MIC for vancomycin was determined using a standardised agar dilution method. Additionally, classification was used to identify the vancomycin AUC24/MIC ratio associated with clinical failure.

Results Of the 151 patients identified, 69 were enrolled. All MICs of vancomycin for E. faecium were ≤1.0 µg/mL. The AUC24 and AUC24/MIC ratio were not significantly different between the clinical failure group and the clinical success group (432±123 µg/mL/hour vs 488±92 µg/mL/hour; p=0.075). However, 7 of 12 patients (58.3%) in the clinical failure group and 49 of 57 patients (86.0%) in the clinical success group had a vancomycin AUC24/MIC ratio ≥389 (p=0.041). No significant association between trough concentration or AUC24 ≥600 µg/mL×hour and acute kidney injury was observed (p=0.365 and p=0.487, respectively).

Conclusion The AUC24/MIC ratio is associated with the clinical outcome of vancomycin administration in E. faecium bacteraemia. In Japan, where vancomycin-resistant enterococcal infection is rare, empirical therapy with a target AUC24 ≥389 should be recommended.

  • Drug Monitoring
  • PHARMACY SERVICE, HOSPITAL
  • Clinical Trial
  • CLINICAL MEDICINE
  • Communicable Diseases

Data availability statement

No data are available. Not applicable. The data that support the findings of this study are available from the corresponding author on reasonable request.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

No data are available. Not applicable. The data that support the findings of this study are available from the corresponding author on reasonable request.

View Full Text